Safety and efficacy of mFOLFOX6+panitumumab combination therapy and 5-FU/LV + panitumumab combination therapy in patients with chemotherapy-naive metastatic colorectal cancer (SAPPHIRE)

被引：0
|
作者：
Nagata, N. [1 ]
Mishima, H. [2 ]
Kurosawa, S. [3 ]
Oba, K. [4 ]
Sakamoto, J. [5 ]
机构：
[1] Kitakyushu Gen Hosp, Surg, Kitakyushu, Fukuoka, Japan
[2] Aichi Med Univ, Clin Oncol, Nagakute, Aichi 48011, Japan
[3] Takeda Pharmaceut Co Ltd, GMA J, Tokyo, Japan
[4] Univ Tokyo, Grad Sch Med, Sch Publ Hlth, Biostat, Tokyo, Japan
[5] Tokai Cent Hosp, Kakamigahara, Japan
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
228TiP
引用
收藏
页码：68 / 68
页数：1
相关论文
共 50 条
  • [1] Safety and Efficacy of mFOLFOX6+Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Patients with Chemotherapy-Naive Metastatic Colorectal Cancer (SAPPHIRE)
    Nagata, N.
    Mishima, H.
    Kurosawa, S.
    Oba, K.
    Sakamoto, J.
    ANNALS OF ONCOLOGY, 2016, 27 : 80 - 80
  • [2] SAPPHIRE: A randomized phase II study of mFOLFOX6+panitumumab versus 5-FU/LV + panitumumab after 6 cycles of frontline mFOLFOX6+panitumumab in patients with colorectal cancer.
    Nakamura, Masato
    Munemoto, Yoshinori
    Takahashi, Masazumi
    Kotaka, Masahito
    Kuroda, Hiroaki
    Kato, Takeshi
    Minagawa, Noritaka
    Noura, Shingo
    Fukunaga, Mutsumi
    Kuramochi, Hidekazu
    Touyama, Tetsuo
    Takahashi, Takao
    Akagi, Yoshito
    Satake, Hironaga
    Kurosawa, Shuichi
    Miura, Tomoko
    Mishima, Hideyuki
    Sakamoto, Junichi
    Oba, Koji
    Nagata, Naoki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [3] A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors
    Autumn J. McRee
    Janine M. Davies
    Hanna G. Sanoff
    Richard M. Goldberg
    Stephen Bernard
    E. Claire Dees
    Kimberly Keller
    Anastasia Ivanova
    Bert H. O’Neil
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 117 - 123
  • [4] A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors
    McRee, Autumn J.
    Davies, Janine M.
    Sanoff, Hanna G.
    Goldberg, Richard M.
    Bernard, Stephen
    Dees, E. Claire
    Keller, Kimberly
    Ivanova, Anastasia
    O'Neil, Bert H.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (01) : 117 - 123
  • [5] SAPPHIRE: A randomized phase II study of oxaliplatin discontinuation after 6 cycles of mFOLFOX6+panitumumab therapy in patients with colorectal cancer: Final analysis of efficacy and safety results
    Takahashi, M.
    Munemoto, Y.
    Nakamura, M.
    Kotaka, M.
    Kuroda, H.
    Kato, T.
    Minagawa, N.
    Noura, S.
    Fukunaga, M.
    Kuramochi, H.
    Touyama, T.
    Takahashi, T.
    Akagi, Y.
    Satake, H.
    Kurosawa, S.
    Miura, T.
    Mishima, H.
    Sakamoto, J.
    Oba, K.
    Nagata, N.
    ANNALS OF ONCOLOGY, 2018, 29
  • [6] Randomized phase II study of maintenance treatment with 5-FU/FA plus panitumumab vs 5-FU/FA alone after induction (mFOLFOX6 plus panitumumab) in patients with RASWT metastatic colorectal cancer
    Modest, D. P.
    Kasper, S.
    Stintzing, S.
    Prasnikar, N.
    Mueller, L.
    Caca, K.
    Goekkurt, E.
    von Weikersthal, L. Fischer
    Kopp, H. -G.
    Trarbach, T.
    ANNALS OF ONCOLOGY, 2016, 27
  • [7] Suramin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in metastatic colorectal cancer patients resistant to 5-FU+LV-based chemotherapy
    Falcone, A
    Pfanner, E
    Brunetti, I
    Allegrini, G
    Lencioni, M
    Galli, C
    Masi, G
    Danesi, D
    Antonuzzo, A
    Del Tacca, M
    Conte, PF
    TUMORI, 1998, 84 (06) : 666 - 668
  • [8] First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study
    Pietrantonio, F.
    Morano, F.
    Corallo, S.
    Raimondi, A.
    Loupakis, F.
    Cremolini, C.
    Smiroldo, V.
    Berenato, R.
    Bianchi, A. Sartore
    Tampellini, M.
    Bustreo, S.
    Clavarezza, M.
    Murialdo, R.
    Zaniboni, A.
    Tomasello, G.
    Peverelli, G.
    Antoniotti, C.
    Procaccio, L.
    Cinieri, S.
    Antonuzzo, L.
    Di Bartolomeo, M.
    de Braud, F.
    ANNALS OF ONCOLOGY, 2018, 29 : 106 - 106
  • [9] Safety and efficacy analysis of imalumab, an anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody, alone or in combination with 5-fluorouracil/leucovorin (5-FU/LV) or panitumumab, in patients with metastatic colorectal cancer (mCRC)
    Mahalingam, D.
    Patel, M.
    Sachdev, J.
    Hart, L.
    Halama, N.
    Ramanathan, R.
    Sarantopoulos, J.
    Liu, X.
    Yazji, S.
    Jaeger, D.
    Adib, D.
    Kerschbaumer, R.
    Yoon, M.
    Manzur, G.
    Starodub, A.
    Sivarajan, K.
    Wertheim, M.
    Thambi, P.
    Jones, M.
    Goel, S.
    Nemunaitis, J.
    Tsimberidou, A.
    ANNALS OF ONCOLOGY, 2016, 27 : 105 - 105
  • [10] mFOLFOX6 Plus Panitumumab Versus 5-FU/LV Plus Panitumumab After Six Cycles of Frontline mFOLFOX6 Plus Panitumumab: A Randomized Phase II Study of Patients With Unresectable or Advanced/Recurrent, RAS Wild-type Colorectal Carcinoma (SAPPHIRE)-Study Design and Rationale
    Nagata, Naoki
    Mishima, Hideyuki
    Kurosawa, Shuichi
    Oba, Koji
    Sakamoto, Junichi
    CLINICAL COLORECTAL CANCER, 2017, 16 (02) : 154 - +
12345